Endometriosis.

Summary

SPRMs have emerged as novel therapeutic approaches for treating endometriosis, particularly for overcoming progesterone resistance, which is a major cause of hormonal treatment failure in endometriosis patients. Reviews covering both experimental studies and clinical trials note that SPRMs offer potential improvements in managing endometriosis where conventional progestin therapy fails due to progesterone receptor dysregulation.

Summary

Long-acting contraceptive drug delivery systems including the levonorgestrel IUS, depot medroxyprogesterone acetate injection, and etonogestrel implant have been repurposed for endometriosis treatment. Reviews of on-label and off-label drug use confirm widespread clinical use of these contraceptive progestin delivery systems for endometriosis symptom relief, particularly chronic pelvic pain and dysmenorrhea, in women with endometriosis. These represent drug delivery platform repurposing where existing contraceptive systems are used for symptomatic management.

Summary

A comprehensive review of plant-derived agents for endometriosis found that Chinese herbal medicine (CHM) formulations have been studied under clinical conditions in women with endometriosis, demonstrating decreased size of endometriotic lesions, alleviation of chronic pelvic pain, and reduced postoperative recurrence rates. The review encompassed both preclinical and clinical studies from systematic literature searches with no date restriction.

Summary

A narrative review prioritizing RCTs, systematic reviews, and meta-analyses proposes that very-low-dose combined oral contraceptives can be used long-term in women with endometriosis for primary prevention (reducing the increased ovarian cancer risk observed in endometriosis patients), secondary prevention (impeding development of advanced disease in adolescents with severe dysmenorrhea), and tertiary management of established disease symptoms. The review specifically recommends avoiding ethinyl estradiol and cyproterone acetate due to thromboembolic and meningioma risks, favoring transdermal estradiol-based regimens.

Summary

Multiple reviews identify oral GnRH antagonists (with add-back therapy for prolonged use) as effective second-line medical treatments for endometriosis in women who are non-responders to first-line hormonal therapies (combined oral contraceptives, progestins). Clinical evidence from RCTs supports their efficacy in reducing endometriosis-associated pain. They are recommended when first-line agents fail, and their use with add-back therapy mitigates hypoestrogenic side effects.

Summary

Azithromycin (AZM) was evaluated as a senolytic drug for endometriosis. In human ovarian endometriosis cyst-derived stromal cells (CSCs) from patients with endometriosis, AZM reduced viable cell fraction (P < 0.001) and suppressed IL-6 expression in culture supernatants (P < 0.05). In a murine endometriosis model, AZM administration reduced endometriotic lesion volume (P < 0.05), decreased proliferative activity (Ki67, P < 0.01), IL-6 expression (P < 0.001), and fibrosis (P < 0.001) within lesions. Human cells from endometriosis patients were used to demonstrate the senescent phenotype (elevated SA-β-Gal, p16INK4a) and the drug's senolytic effects in vitro, while in vivo confirmation was in a mouse model.

Summary

In NCT00704912, clomiphene citrate produced dysmenorrhea (n=20 total), pelvic pain (n=42 total), abnormal uterine bleeding (n=11 total), and abdominal pain (n=23 total) in PCOS women. These pain and bleeding patterns are directly relevant to endometriosis symptomatology. Clomiphene's estrogen receptor modulation could alter estrogen-dependent endometrial implant behavior.

Summary

In NCT03480022, liraglutide 3mg produced prolonged menstrual bleeding (n=4) in obese PCOS women. Altered menstrual bleeding patterns in the context of metabolic improvement (weight loss, insulin sensitization) may also have implications for endometriosis, as reduced hyperinsulinemia and adipose tissue mass lower peripheral estrogen production and inflammatory cytokines relevant to ectopic endometrial tissue.

Summary

In NCT00427700 and NCT01607320, raloxifene was studied for ovulation induction in PCOS patients. Reported AEs included pelvic pain (n=1), headache (n=3), and abdominal bloating (n=1). Raloxifene is a selective estrogen receptor modulator (SERM) that acts as an estrogen antagonist in uterine tissue, which is mechanistically relevant to estrogen-dependent conditions including endometriosis.

Summary

In NCT00927095, continuous oral contraceptive use in PMDD patients tracked bloating (n=25) and pelvic-adjacent symptoms alongside mood AEs. Continuous OC regimens suppress ovulation and create a stable hormonal milieu that reduces estrogen-dependent endometrial proliferation and inflammation relevant to endometriosis. The suppression of cyclical hormonal fluctuations that drives the PMDD indication also addresses the estrogen-driven inflammatory and proliferative pathways in endometriosis.

Summary

In NCT03749109, quinagolide vaginal ring was specifically studied for MRI-assessed lesion reduction in women with endometriosis/adenomyosis. Reported AEs included abdominal distension (n=3) and headache (n=14), which are common symptoms in endometriosis. The trial's primary design targeting lesion reduction suggests direct investigation of quinagolide's anti-angiogenic and anti-proliferative effects on endometriotic implants.

Summary

Tanezumab is an anti-NGF (nerve growth factor) monoclonal antibody in Phase 2 for endometriosis-associated pain. NGF is upregulated in endometriotic lesions where it drives neuroangiogenesis — the co-growth of sensory nerve fibers and blood vessels. This connects to the genetically validated KDR/VEGFR-2 pathway (genetic association 0.93) since NGF and VEGF share reciprocal upregulation in the endometriotic microenvironment. The drug targets pain neuroplasticity rather than hormonal pathways.

Summary

Prinaberel is a selective estrogen receptor beta (ERβ/ESR2) agonist in Phase 2 for endometriosis. While ESR1 (overall 0.670) drives proliferative and inflammatory effects in endometriosis, ERβ activation opposes ESR1 signaling by inducing anti-proliferative and pro-apoptotic gene programs. ERβ agonism also suppresses Wnt4 pathway activity (Wnt4 genetic association 0.71), which is implicated in endometrial cell fate and progesterone resistance.

Summary

Bentamapimod is a JNK (c-Jun N-terminal kinase) inhibitor targeting MAPK8/9/10, currently in Phase 2 for endometriosis. JNK signaling is a downstream effector of IL-1α (endometriosis association score 0.469, literature 0.84) and mediates estrogen receptor 1 ligand-independent activation via phosphorylation of AF-1 domains. ESR1 has the highest overall association with endometriosis (0.670). JNK also drives MMP expression critical for tissue invasion by ectopic endometrium.

Summary

Cabergoline is a dopamine D2 receptor agonist approved for hyperprolactinemia. In endometriosis, dopamine D2 receptor activation has been shown to inhibit VEGF-driven angiogenesis via suppression of VEGFR-2 (kinase insert domain receptor, KDR) phosphorylation. KDR has one of the highest genetic association scores for endometriosis (0.93), and cabergoline is already in Phase 2 trials for this condition, suggesting the dopamine-angiogenesis axis is a validated but underappreciated pathway link.

Summary

Filgrastim is a G-CSF receptor agonist (CSF3R) approved for neutropenia, in Phase 2 for endometriosis-related fertility. G-CSF signaling modulates endometrial receptivity and implantation through effects on uterine NK cells and stromal decidualization. While the link to endometriosis pathology is indirect, G-CSF may counteract the impaired decidualization and altered immune microenvironment seen in endometriosis-associated infertility, potentially via R-spondin 3/Wnt pathway modulation (RSPO3 genetic association 0.83).

Summary

Rosiglitazone is a PPARγ agonist approved for type 2 diabetes, currently in Phase 2 for endometriosis. PPARγ activation directly antagonizes estrogen receptor 1 (ESR1) transcriptional activity via competition for shared coactivators and suppresses NF-κB-driven inflammatory cytokine production including IL-1α (literature score 0.84). ESR1 is the top-scoring target for endometriosis (overall 0.670, clinical 0.90), and IL-1α has a genetic association score of 0.73.

Summary

Anastrozole is an aromatase (CYP19A1) inhibitor approved for breast cancer. CYP19A1 is locally overexpressed in endometriotic lesions where it drives local estrogen biosynthesis independent of ovarian function. ESR1 has the highest overall association with endometriosis (0.670, clinical 0.90), and local aromatase activity in lesions creates an autocrine estrogen loop. Growth regulating estrogen receptor binding 1 (GREB1, genetic association 0.80) is a direct ESR1 transcriptional target that mediates estrogen-driven proliferation.

Summary

Pentoxifylline is a phosphodiesterase inhibitor and adenosine A2 receptor antagonist approved for peripheral vascular disease, in Phase 3 for endometriosis. PDE3/4A inhibition increases intracellular cAMP, which suppresses TNF-α and IL-1α production from peritoneal macrophages. IL-1α has a combined association score of 0.469 with endometriosis (literature 0.84, genetic 0.73). Adenosine A2 receptor blockade further reduces fibrotic and angiogenic signaling relevant to lesion maintenance.

Summary

Aspirin irreversibly inhibits cyclooxygenase-1 and -2 (PTGS1/PTGS2), the rate-limiting enzymes in prostaglandin biosynthesis. Adenomyotic lesions exhibit marked COX-2 (PTGS2) overexpression driving prostaglandin E2-mediated pain, local estrogen production (PGE2 stimulates aromatase), and angiogenesis. The COX-2/PGE2/aromatase positive feedback loop is a well-characterized pathogenic circuit in adenomyosis.

Summary

Letrozole inhibits CYP19A1 (aromatase), which has an Open Targets association score of 0.207 for adenomyosis with strong literature evidence (0.69). CYP19A1 is overexpressed in adenomyotic lesions, driving local estrogen biosynthesis independent of ovarian production. The genetic and literature convergence on aromatase as a disease-associated target provides a specific molecular rationale for aromatase inhibition in adenomyosis.

Summary

Bromocriptine is a D2-like dopamine receptor agonist listed at Phase 1 for adenomyosis. Prolactin, suppressed by dopamine D2 agonism, is elevated in some adenomyosis patients and promotes local estrogen production and immune dysregulation in endometrial tissue. The dopamine-prolactin-estrogen axis represents a non-obvious neuroendocrine pathway contributing to adenomyotic lesion growth.

Summary

Epelsiban is an oxytocin receptor antagonist developed for preterm labor and IVF implantation support, currently in Phase 2 for adenomyosis. Adenomyosis involves aberrant uterine contractility driven by oxytocin signaling in the junctional zone myometrium. Oxytocin receptor overexpression in adenomyotic tissue drives dysperistalsis, retrograde menstruation, and pain — the oxytocin-myometrial contractility axis is a specific non-hormonal target in this condition.

Summary

Out of 50,392 condition-relevant adverse event reports for simvastatin in the FDA AEMS database (from 126,236 total female-patient reports), the data reveals a convergent pattern of mood/neurological symptoms (fatigue n=23, asthenia n=16, insomnia n=10, depression n=5, anxiety n=1, crying n=1), vasomotor symptoms (hot flush n=3, flushing n=3, night sweats n=1, cold sweat n=1), and a direct report of endometriosis (n=1). Simvastatin's known anti-inflammatory and anti-proliferative properties via the mevalonate pathway have been investigated in preclinical endometriosis models, and the presence of both an endometriosis report and estrogen-modulating signals suggests mechanistic relevance. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 5,981 condition-relevant adverse event reports for lovastatin in the FDA AEMS database (from 13,990 total female-patient reports), the pain and inflammatory signal profile — abdominal pain (n=11), chest pain (n=12), pain (n=17), abdominal distension (n=2), joint swelling (n=2), oedema (n=2), gastrointestinal inflammation (n=1) — combined with vaginal haemorrhage (n=1) and mood symptoms (depression n=3, anxiety n=3) spans multiple endometriosis-relevant domains. Lovastatin's well-characterized anti-inflammatory mechanism through mevalonate pathway inhibition has preclinical support in endometriosis models. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 46,392 condition-relevant adverse event reports for rosuvastatin in the FDA AEMS database (from 107,207 total female-patient reports), a rich pain-inflammatory signal emerges: abdominal pain (upper n=7, general n=5), pelvic-area reports (ovarian cyst n=1, uterine haemorrhage n=1, uterine cyst n=1), and inflammatory markers (swelling n=6, peripheral swelling n=5, inflammation n=2, oedema peripheral n=2, joint swelling n=2). Combined with strong mood symptoms (depression n=7, anxiety n=6), this multi-domain pattern aligns with endometriosis symptomatology. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 3,742 condition-relevant adverse event reports for pravastatin in the FDA AEMS database (from 10,007 total female-patient reports), abdominal and pelvic pain signals (abdominal pain n=6, back pain n=9, headache n=12) combined with prominent inflammatory markers (peripheral swelling n=5, oedema peripheral n=4, swelling n=2, inflammation n=1, joint swelling n=1) and menstrual irregularity (n=1) are relevant to endometriosis symptomatology. Pravastatin's anti-inflammatory and anti-angiogenic properties have been specifically studied in preeclampsia and endometriosis models. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 48,546 condition-relevant adverse event reports for atorvastatin in the FDA AEMS database (from 123,129 total female-patient reports), the convergence of abdominal pain (upper n=6, lower n=4), pelvic fracture (n=1), inflammatory markers (swelling n=4, oedema peripheral n=4, joint swelling n=2), and mood symptoms (fatigue n=13, asthenia n=11, anxiety n=3) forms a pattern relevant to endometriosis. Atorvastatin's potent suppression of NF-κB and pro-inflammatory cytokines through mevalonate pathway inhibition has demonstrated anti-endometriotic effects in preclinical models. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 19,586 condition-relevant adverse event reports for semaglutide in the FDA AEMS database (from 47,253 total female-patient reports), abdominal and pelvic pain signals were substantial including abdominal pain upper (n=12), abdominal pain (n=12), abdominal distension (n=6), abdominal discomfort (n=5), and back pain (n=10), alongside inflammatory markers such as peripheral swelling (n=7), joint swelling (n=5), and inflammatory marker increased (n=1). While GI-related pain is expected with GLP-1 agonists, the inflammatory signal co-occurrence raises the question of whether prostaglandin or NF-κB modulation by GLP-1 signaling may interact with estrogen-driven inflammatory pathways in endometriosis. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 25,166 condition-relevant adverse event reports for tirzepatide in the FDA AEMS database (from 74,456 total female-patient reports), substantial pain and inflammatory signals relevant to endometriosis were identified, including widespread pain (n=28), abdominal pain (n=2), abdominal pain upper (n=4), abdominal pain lower (n=1), abdominal discomfort (n=6), back pain (n=10), and peripheral swelling (n=6), alongside abdominal distension (n=4), joint swelling (n=3), and inflammatory bowel disease (n=1). The intermenstrual bleeding report (n=1) adds a menstrual-cycle dimension. The anti-inflammatory properties of GLP-1/GIP dual agonism via NF-κB and TNF-α suppression are mechanistically relevant to estrogen-driven inflammatory conditions. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 4,176 condition-relevant adverse event reports for pramipexole in the FDA AEMS database (from 10,301 total female-patient reports), extensive pain signals included pain (n=22), back pain (n=14), headache (n=11), pain in extremity (n=10), abdominal pain (n=6), and abdominal discomfort (n=5), alongside peripheral inflammatory signals (peripheral swelling n=10, oedema peripheral n=7, joint swelling n=4). The general sample showed weight decreased (n=3) and hypoglycaemia (n=2), consistent with metabolic modulation. These widespread pain and inflammatory signals, though largely from Parkinson's/RLS populations, demonstrate pramipexole's modulation of central pain processing pathways relevant to endometriosis-associated chronic pelvic pain. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 4,313 condition-relevant adverse event reports for ropinirole in the FDA AEMS database (from 10,302 total female-patient reports), extensive pain signals including headache (n=15), pain (n=14), pain in extremity (n=9), abdominal pain (n=6), abdominal distension (n=5), and back pain (n=3), combined with inflammatory markers (peripheral swelling n=7, oedema peripheral n=4, joint swelling n=2), and uterine-specific findings (uterine leiomyoma n=1, uterine polyp n=1, dysmenorrhoea n=1) constitute a pain-inflammatory signal relevant to endometriosis. Ropinirole's dopaminergic modulation of spinal and supraspinal pain processing pathways, combined with anti-inflammatory properties of D2 receptor activation on immune cells, may modulate endometriosis-associated central sensitization. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 34,200 condition-relevant adverse event reports for citalopram in the FDA AEMS database (from 83,257 total female-patient reports), pain and pelvic signals relevant to endometriosis were prominent including pelvic pain (n=3), abdominal pain (n=10), abdominal distension (n=5), abdominal pain upper (n=3), abdominal discomfort (n=3), pain (n=14), headache (n=6), alongside uterine perforation (n=3), dyspareunia (n=1), and prominent mood comorbidity (depression n=18, fatigue n=14, anxiety n=5). The direct pelvic pain and dyspareunia signals combined with inflammatory markers (gastrointestinal inflammation n=2, joint swelling n=3) suggest endometriosis-relevant pathology. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 36,976 condition-relevant adverse event reports for escitalopram in the FDA AEMS database (from 85,593 total female-patient reports), pain signals relevant to endometriosis were prominent including abdominal pain (n=9), pain (n=17), abdominal discomfort (n=6), migraine (n=6), back pain (n=5), neck pain (n=5), musculoskeletal pain (n=4), alongside uterine findings (uterine perforation n=4, uterine leiomyoma n=1, uterine haemorrhage n=1) and mood comorbidity (depression n=12, anxiety n=9). The high abdominal/pelvic pain burden with uterine pathology signals supports relevance to the endometriosis pain-mood axis. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 54,612 condition-relevant adverse event reports for sertraline in the FDA AEMS database (from 130,278 total female-patient reports), pain signals relevant to endometriosis were identified including abdominal pain (n=5), abdominal pain upper (n=8), pelvic-adjacent pain (n=18 general pain), headache (n=17), and migraine (n=1), alongside inflammatory markers (joint swelling n=3) and mood comorbidity signals (depression n=16, anxiety n=12). Serotonin plays a dual role in pain modulation and inflammatory signaling in endometriotic lesions; these signals may reflect both the treated comorbid population and SSRI effects on central pain sensitization. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 35,251 condition-relevant adverse event reports for fluoxetine in the FDA AEMS database (from 83,971 total female-patient reports), pain and inflammatory signals relevant to endometriosis were identified including abdominal pain (n=11), pain (n=16), pain in extremity (n=12), migraine (n=4), back pain (n=4), alongside a direct endometriosis report (n=1), uterine perforation (n=2), uterine leiomyoma (n=1), and prominent mood comorbidity (depression n=17, anxiety n=14). The co-occurrence of pelvic-abdominal pain, endometriosis as an indication, and mood symptoms is consistent with serotonergic modulation of the central pain-mood axis in endometriosis. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 17,165 condition-relevant adverse event reports for meloxicam in the FDA AEMS database (from 37,086 total female-patient reports), the adenomyosis (n=1) and ovarian cyst (n=1) reports, alongside abdominal/pelvic pain (abdominal pain n=7, pain n=27), menorrhagia (n=1), inflammatory signals (peripheral swelling n=9), and uterine structural changes (uterine leiomyoma n=1, uterine polyp n=1) form a pattern directly relevant to endometriosis. The shared estrogen-PGE2 pathway between adenomyosis and endometriosis signals strengthens this finding. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 37,836 condition-relevant adverse event reports for diclofenac in the FDA AEMS database (from 86,286 total female-patient reports), a direct endometriosis report (n=1) co-occurs with substantial pain signals (pain n=17, abdominal pain upper n=7, abdominal pain n=2, back pain n=4, chest pain n=3), ovarian cysts (n=2), and inflammatory markers (lip swelling n=8, periorbital oedema n=5, peripheral swelling n=3). The mood cluster (depression n=5, anxiety n=5, insomnia n=3) reflects chronic pain comorbidity. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 68,147 condition-relevant adverse event reports for ibuprofen in the FDA AEMS database (from 159,407 total female-patient reports), there is a substantial pattern of dysmenorrhoea, menorrhagia, pelvic pain, and uterine pain reports alongside a direct endometriosis report, despite ibuprofen being a first-line treatment for endometriosis-related pain. This paradoxical pattern suggests that while COX inhibition provides symptomatic relief, prostaglandin pathway modulation may be insufficient to address estrogen-driven inflammatory progression, and rebound or breakthrough pain may occur. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 36,972 condition-relevant adverse event reports for celecoxib in the FDA AEMS database (from 83,065 total female-patient reports), substantial pain and inflammatory signals (pain n=29, abdominal discomfort n=8, abdominal pain upper n=6, joint swelling n=4, peripheral swelling n=4, inflammation n=1) emerge despite celecoxib being a selective COX-2 inhibitor prescribed for pain. Celecoxib's COX-2 selectivity is of direct mechanistic interest for endometriosis given COX-2 overexpression in ectopic endometrial lesions. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 2,594 condition-relevant adverse event reports for indomethacin in the FDA AEMS database (from 5,941 total female-patient reports), uterine pathology signals are disproportionately prominent: uterine perforation (n=3), uterine rupture (n=2), uterine haemorrhage (n=2), pelvic pain (n=2), endometrial hyperplasia (n=1), leiomyoma (n=1), and ovarian cyst (n=1), alongside abdominal pain (n=11) and menorrhagia (n=2). This uterine signal cluster in a relatively small dataset suggests high reporting density for endometriosis-relevant pathology. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 38,880 condition-relevant adverse event reports for naproxen in the FDA AEMS database (from 85,294 total female-patient reports), pelvic pain (n=2), abdominal pain (n=14), dysmenorrhoea (n=1), menorrhagia (n=1), and uterine haemorrhage (n=1) alongside inflammatory markers (peripheral swelling n=10, inflammation n=3) form a consistent endometriosis-relevant signal pattern. Naproxen is commonly prescribed for dysmenorrhoea but persistent pain reports suggest incomplete disease control. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 8,735 condition-relevant adverse event reports for exemestane in the FDA AEMS database (from 18,954 total female-patient reports), pelvic pain (n=1), uterine haemorrhage (n=1), abdominal pain (n=3), abdominal pain upper (n=5), inflammatory signals (oedema peripheral n=4, inflammation n=2, mucosal inflammation n=3, joint swelling n=2), and amenorrhoea (n=1) are relevant to endometriosis. Exemestane, like other aromatase inhibitors, targets the CYP19A1 overexpressed in endometriotic lesions and has published evidence supporting use in refractory endometriosis, particularly due to its irreversible mechanism providing sustained estrogen suppression. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 89,421 condition-relevant adverse event reports for metformin in the FDA AEMS database (from 212,759 total female-patient reports), inflammatory markers (oedema, swelling, gastrointestinal inflammation) and pain signals (abdominal pain, pelvic-adjacent pain) appear alongside the drug's known AMPK-activating anti-inflammatory properties. Metformin's ability to suppress NF-κB signaling and reduce estrogen biosynthesis via aromatase inhibition suggests mechanistic relevance to endometriosis, where estrogen-driven inflammation drives disease progression. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 28,321 condition-relevant adverse event reports for spironolactone in the FDA AEMS database (from 73,834 total female-patient reports), endometriosis was directly reported as an adverse event (n=1) alongside pelvic pain (n=2), abdominal pain (n=4), abdominal pain lower (n=2), uterine haemorrhage (n=1), menorrhagia (n=1), and inflammatory markers including peripheral oedema (n=8) and oedema (n=6). Spironolactone's anti-androgenic and progestogenic activity may modulate estrogen-androgen balance relevant to endometriotic lesion biology, and the presence of pelvic pain and inflammatory signals alongside a direct endometriosis report warrants attention. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 8,493 condition-relevant adverse event reports for naltrexone in the FDA AEMS database (from 18,974 total female-patient reports), abdominal and pelvic pain signals were prominent (abdominal pain n=6, abdominal pain upper n=6, abdominal discomfort n=4, pain n=7) alongside inflammatory markers (peripheral swelling n=3, joint swelling n=2, inflammation n=1) and mood disturbance. Low-dose naltrexone (LDN) is already under clinical investigation for endometriosis pain due to its paradoxical immunomodulatory effects at sub-therapeutic doses, and these AEMS data at standard doses may reflect opioid-receptor-mediated disruption of endogenous pain modulation in estrogen-primed pelvic tissues. Full-scale analysis of all reports may reveal additional patterns.

Summary

A user's husband reported that linaclotide (Linzess), an IBS-C medication, dramatically reduced his wife's endometriosis pain after resolving severe constipation in one dose. The hypothesis is that bowel congestion/constipation exacerbates endo pain, and resolving it provides significant relief. While the primary detailed report comes from one post, multiple other posts describe the bowel-endo pain connection and constipation management as critical for endo symptom control.

Summary

Multiple trans men and nonbinary individuals report that testosterone therapy unexpectedly eliminated or dramatically reduced their endometriosis symptoms, including pain, migraines, PMDD, and painful bowel movements. Symptoms returned when testosterone was stopped or reduced. This represents a surprising off-label finding since testosterone is not prescribed for endometriosis.